Op-Ed: mRNA flu vaccine shows promise. Federal policy may kill it

The mRNA flu vaccine, which has shown promising results in offering better protection than traditional vaccines, faces potential setbacks due to federal policy hurdles. This intersection of innovative science and political challenges could hinder widespread availability, despite the potential benefits in public health. The implications are significant, as timely access to advanced vaccines could drastically improve flu prevention and reduce the burden on healthcare systems. This situation underscores the need for a balance between regulatory oversight and the rapid deployment of life-saving technologies.